Stockreport

Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue [Seeking Alpha]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Enhertu, the primary revenue driver today, has shown promising results in HER2+ breast cancer, while Dato-DXd offers billions in potential revenue from lung and breast [Read more]